DURHAM, N.C. & SEATTLE--January 12, 2025--Leading epigenome editing company Tune Therapeutics (Tune) today announced the completion of over $175M in financing led by New Enterprise Associates, Yosemite, Regeneron Ventures and...
Elitra, whose assets were acquired by Merck in 2004, was an antimicrobial functional genomics company that focused on the identification, development and commercialization of novel antimicrobial compounds that target essential gene products of pathogenic organisms.
Elitra Phramaceuticals
San Diego, CA
© 2024 Pappas Capital, LLC. ALL RIGHTS RESERVED.